Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma
- PMID: 26442832
- DOI: 10.1136/jclinpath-2015-203107
Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma
Abstract
Aims: As numerous signalling molecules regulate effector functions of peripheral blood lymphocytes (PBLs) that have an important anti-tumour activity, the aim of this study was to analyse their level in patients with metastatic melanoma (MM) compared with healthy controls (HCs).
Methods: Peripheral blood mononuclear cells (PBMCs) of 36 MMs and 28 HCs were analysed for the level of perforin, interferon-regulating transcription factor-1 (IRF-1), DAP10 and Src homology 2 domain-containing tyrosine phosphatase-1 by reverse transcriptase PCR, level of phosphorylated signal transducers and activators of transcription (pSTAT)-1, pSTAT-4, pSTAT-5 by western blot and interferon (IFN)-γ production by ELISA. The expression of activating NKG2D and inhibitory killer immunoglobulin-like receptors (KIR), CD158a and CD158b, on PBL, CD3-CD56+ natural killer (NK) cells and CD3+CD8+ cytotoxic T lymphocytes (CTLs), as well as the percentage of CD14+HLA-DR- cells in PBMC were estimated by flow cytometry.
Results: Patients with MM, compared with HCs, had significantly lower level of cytotoxic molecule perforin and decreased IFN-γ production, as well as lower level of pSTAT-1, pSTAT-4, pSTAT-5 and IRF-1 signalling molecules in PBMC. Furthermore, MM had decreased expression of activating NKG2D receptor on PBL and NK cells and low level of its DAP10 signalling molecule contrary to no changes in KIR expression on all investigated cells. These results could be associated with increased percentage of immunosuppressive CD14+HLA-DR- myeloid-derived suppressor cells detected in patients with MM.
Conclusions: The altered signalling molecules of PBL could represent biomarkers of impaired cytotoxic and immunoregulatory function of these cells, indicating melanoma-associated immunosuppression that facilitates tumour progression.
Keywords: CELL CYCLE REGULATION; IMMUNOPHENOTYPING; MELANOMA.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.Melanoma Res. 2014 Aug;24(4):295-304. doi: 10.1097/CMR.0000000000000072. Melanoma Res. 2014. PMID: 24769842
-
The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients.J Surg Res. 2011 Dec;171(2):637-49. doi: 10.1016/j.jss.2010.05.012. Epub 2010 Jun 8. J Surg Res. 2011. PMID: 20828749
-
Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.J Transl Med. 2015 Apr 14;13:120. doi: 10.1186/s12967-015-0479-z. J Transl Med. 2015. PMID: 25889680 Free PMC article.
-
Attenuated in vitro effects of IFN-α, IL-2 and IL-12 on functional and receptor characteristics of peripheral blood lymphocytes in metastatic melanoma patients.Cytokine. 2017 Aug;96:30-40. doi: 10.1016/j.cyto.2017.02.024. Epub 2017 Mar 7. Cytokine. 2017. PMID: 28282548
-
Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells.Biomarkers. 2009 Jun;14(4):258-70. doi: 10.1080/13547500902814658. Biomarkers. 2009. PMID: 19489688
Cited by
-
Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC.Front Immunol. 2020 Jan 15;10:3095. doi: 10.3389/fimmu.2019.03095. eCollection 2019. Front Immunol. 2020. PMID: 32010142 Free PMC article.
-
Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma.Transl Oncol. 2021 Jan;14(1):100872. doi: 10.1016/j.tranon.2020.100872. Epub 2020 Sep 23. Transl Oncol. 2021. PMID: 32979685 Free PMC article.
-
Deciphering the molecular and clinical characteristics of TREM2, HCST, and TYROBP in cancer immunity: A comprehensive pan-cancer study.Heliyon. 2024 Feb 28;10(5):e26993. doi: 10.1016/j.heliyon.2024.e26993. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38468942 Free PMC article.
-
IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway.Cancer Manag Res. 2018 Dec 31;11:369-378. doi: 10.2147/CMAR.S186236. eCollection 2019. Cancer Manag Res. 2018. PMID: 30643462 Free PMC article.
-
The multiple roles of interferon regulatory factor family in health and disease.Signal Transduct Target Ther. 2024 Oct 9;9(1):282. doi: 10.1038/s41392-024-01980-4. Signal Transduct Target Ther. 2024. PMID: 39384770 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous